Retatrutide is an investigational "triple-agonist" peptide for treating obesity, type 2 diabetes, and related metabolic conditions. In phase 2 clinical trials, it demonstrated significant weight loss, improving metabolic markers and potentially reversing fatty liver disease.

It is crucial to note that this Peptide  is a research chemical not approved for human consumption by the FDA, and its therapeutic use has not been clinically established.